Yes. Utilizing genetic fingerprints to predict patient response to drugs in early-phase clinical development, pharmacogenomics are used in the pharmaceutical industry in their endeavour to produce new drugs that are highly efficient in terms of safety and efficacy.

Researchers are now using genomic information to find or design drugs aimed at subgroups of patients with specific genetic profiles.

Researchers are also using pharmacogenomic tools to search for drugs that target specific molecular and cellular pathways involved in disease.

Read more detail in e.g., Burt and Dhillon, Pharmacogenomics in early-phase clinical development, Pharmacogenomics. 2013 July ; 14(9): 1085-1097